Plus therapeutics to present at inaugural targeted radiopharmaceuticals summit

Austin, texas, july 27, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that norman lafrance, m.d., chief medical officer and svp will give a presentation on the company's lead investigational targeted radiotherapeutic, rhenium-186 nanoliposome (186rnl), and share updates on the u.s. respect clinical trials at the inaugural targeted radiopharmaceuticals summit, organized by hanson wade, being held july 26-28, 2022 at the boston park plaza in boston, massachusetts.
pstv Ratings Summary
pstv Quant Ranking